Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01300728 · ClinicalTrials.gov registry record · Phase 2
Study of Intravenous Immunoglobulin in Amnestic Mild Cognitive Impairment
A Phase 2 study, sponsored by Sutter Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
NCT01300728 is a Phase 2 study that has completed, run by Sutter Health. The registered enrollment target is 52 participants.
The verdict
NCT01300728, a Phase 2 study, has completed, sponsored by Sutter Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
Study Summary
Patients with mild cognitive impairment (MCI) are a group recognized at being at high risk of progressing to Alzheimer disease. Treatment of MCI with immunotherapy with intravenous immunoglobulins (IVIG) could potentially reduce the risk of progression to Alzheimer disease. This study will evaluate the efficacy of intravenous immunoglobulin in patients with MCI over 24 months after the first infusion. This study will also document conversion from MCI to Alzheimer's Disease.
Interventions
- OTHER Placebo
- DRUG NewGam 10% IVIG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2011-01-01 |
| Est. Completion | 2020-03-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01300728
The ClinicalTrials.gov registry entry for NCT01300728 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sutter Health, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01300728 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01300728 about?
NCT01300728 is a clinical study titled "Study of Intravenous Immunoglobulin in Amnestic Mild Cognitive Impairment". Patients with mild cognitive impairment (MCI) are a group recognized at being at high risk of progressing to Alzheimer disease. Treatment of MCI with immunotherapy with intravenous immunoglobulins (IVIG) could potentially reduce the risk of progression to Alzheimer disease. This study will evaluate...
What is the current status of trial NCT01300728?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2011-01-01. Estimated completion is 2020-03-12.
What interventions are being tested in trial NCT01300728?
The interventions under investigation include: Placebo (OTHER), NewGam 10% IVIG (DRUG).
Who is sponsoring clinical trial NCT01300728?
This trial is sponsored by Sutter Health, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.